{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:02:08Z","timestamp":1761897728136,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000689","81974094"],"award-info":[{"award-number":["82000689","81974094"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2021M691212"],"award-info":[{"award-number":["2021M691212"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s10157-022-02263-4","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T09:06:11Z","timestamp":1661418371000},"page":"1043-1054","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in maintenance dialysis: a meta-analysis"],"prefix":"10.1007","volume":"26","author":[{"given":"Meiyan","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongsen","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuzhe","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonggao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"2263_CR1","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1053\/j.ajkd.2006.03.010","volume":"47","author":"KDOQI; National kidney foundation","year":"2006","unstructured":"KDOQI; National kidney foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47:S11\u2013145.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"2263_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nrneph.2015.82","volume":"11","author":"JK Mark","year":"2015","unstructured":"Mark JK, Volker HH. Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol. 2015;11(7):394\u2013410.","journal-title":"Nat Rev Nephrol"},{"issue":"21","key":"2263_CR3","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","volume":"361","author":"MA Pfeffer","year":"2009","unstructured":"Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019\u201332.","journal-title":"N Engl J Med"},{"issue":"12","key":"2263_CR4","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1681\/ASN.2010010116","volume":"21","author":"WM Bernhardt","year":"2010","unstructured":"Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010;21(12):2151\u20136.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"2263_CR5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nrneph.2015.82","volume":"11","author":"MJ Koury","year":"2015","unstructured":"Koury MJ, Haase VH. Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol. 2015;11(7):394\u2013410.","journal-title":"Nat Rev Nephrol"},{"key":"2263_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"2263_CR7","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"2263_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med"},{"issue":"4","key":"2263_CR9","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1681\/ASN.2014111139","volume":"27","author":"H Louis","year":"2016","unstructured":"Louis H, Amy MM, Rayma M, et al. Four-week studies of ora l hypoxia- inducible factor- prolyl Hydroxylase inhibitor GSK1278863 for treatment of anemia. JASN. 2016;27(4):1234\u201344.","journal-title":"JASN"},{"issue":"6","key":"2263_CR10","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","volume":"67","author":"AB Richard","year":"2016","unstructured":"Richard AB, Brendan J, Coreen O, et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2A randomized trial. Am J Kidney Dis. 2016;67(6):861\u201371.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2263_CR11","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","volume":"67","author":"R Provenzano","year":"2016","unstructured":"Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016;67(6):912\u201324.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2263_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000454818","volume":"45","author":"T Akizawa","year":"2017","unstructured":"Akizawa T, Tsubakihara Y, Nangaku M, et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. Am J Nephrol. 2017;45(2):127\u201335.","journal-title":"Am J Nephrol"},{"issue":"8","key":"2263_CR13","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","volume":"32","author":"N Chen","year":"2017","unstructured":"Chen N, Qian J, Chen J, et al. Phase 2 studies of oral hypoxia-inducible factor prolylhydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant. 2017;32(8):1373\u201386.","journal-title":"Nephrol Dial Transplant"},{"key":"2263_CR14","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s12882-019-1547-z","volume":"20","author":"CK Bailey","year":"2019","unstructured":"Bailey CK, Caltabiano S, Cobitz AR, et al. A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly inpatients with anemia on hemodialysis. BMC Nephrol. 2019;20:372.","journal-title":"BMC Nephrol"},{"issue":"1","key":"2263_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ckj\/sfy014","volume":"12","author":"A Meadowcroft","year":"2019","unstructured":"Meadowcroft A, Cizman B, Holdstock L, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clin Kidney J. 2019;12(1):139\u201348.","journal-title":"Clin Kidney J"},{"key":"2263_CR16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Liu B-C, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381:1011\u201322.","journal-title":"N Engl J Med"},{"issue":"2","key":"2263_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000500487","volume":"143","author":"T Akizawa","year":"2019","unstructured":"Akizawa T, Nangaku M, Yamaguchi T, et al. Enarodustat, conversion and maintenance therapy for anemia in hemodialysis patients: a randomized, placebo-controlled phase 2b trial followed by long-term trial. Nephron. 2019;143(2):77\u201385.","journal-title":"Nephron"},{"key":"2263_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2215\/CJN.02510218","volume":"14","author":"IC Macdougall","year":"2019","unstructured":"Macdougall IC, Akizawa T, Berns JS, et al. Effects of molidustat in the treatment of anemia in CKD. Clin J Am Soc Nephrol. 2019;14:28\u201339.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2263_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000499111","volume":"49","author":"T Akizawa","year":"2019","unstructured":"Akizawa T, Macdougall IC, Berns JS, et al. Long-term efficacy and safety of molidustat for anemia in chronic kidney disease: DIALOGUE extension studies. Am J Nephrol. 2019;49:271\u201380.","journal-title":"Am J Nephrol"},{"issue":"7","key":"2263_CR20","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1681\/ASN.2019060623","volume":"31","author":"T Akizawa","year":"2020","unstructured":"Akizawa T, Iwasaki M, Yamaguchi Y, et al. Phase 3, randomized, double-blind, active-comparator (Darbepoetin Alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. J Am Soc Nephrol. 2020;31(7):1628\u201339.","journal-title":"J Am Soc Nephrol"},{"key":"2263_CR21","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","volume":"38","author":"B Csiky","year":"2021","unstructured":"Csiky B, Schomig M, Esposito C, et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a european phase 3, randomized, open-label active-controlled study PYRENEES. Adv Ther. 2021;38:5361\u201380.","journal-title":"Adv Ther"},{"key":"2263_CR22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1159\/000517053","volume":"7","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Nangaku M, Yamaguchi T, et al. A phase 3 study of enarodustat (JTZ-951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD study. Kidney Dis. 2021;7:494\u2013502.","journal-title":"Kidney Dis"},{"key":"2263_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000450779","volume":"189","author":"F Locatelli","year":"2017","unstructured":"Locatelli F, Del VL. New strategies for anaemia management in chronic kidney disease. Contrib Nephrol. 2017;189:184\u20138.","journal-title":"Contrib Nephrol"},{"key":"2263_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","volume":"30","author":"WG Kaelin","year":"2008","unstructured":"Kaelin WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30:393\u2013402.","journal-title":"Mol Cell"},{"key":"2263_CR25","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1182\/blood-2003-02-0448","volume":"102","author":"M Scortegagna","year":"2003","unstructured":"Scortegagna M, Morris MA, Oktay Y, et al. The HIF family member EPAS1\/HIF-2\u03b1 is required for normal hematopoiesis in mice. Blood. 2003;102:1634\u201340.","journal-title":"Blood"},{"key":"2263_CR26","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1126\/science.1104742","volume":"306","author":"E Nemeth","year":"2004","unstructured":"Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090\u20133.","journal-title":"Science"},{"key":"2263_CR27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/ki.2014.275","volume":"87","author":"GR Bailie","year":"2015","unstructured":"Bailie GR, Larkina M, Goodkin DA, et al. Data from the dialysis outcomes and practice patterns study validate an association between high intravenous iron doses and mortality. Kidney Int. 2015;87:162\u20138.","journal-title":"Kidney Int"},{"key":"2263_CR28","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1172\/JCI0215686","volume":"110","author":"G Nicolas","year":"2002","unstructured":"Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110:1037\u201344.","journal-title":"J Clin Invest"},{"key":"2263_CR29","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1172\/JCI31370","volume":"117","author":"C Peyssonnaux","year":"2007","unstructured":"Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Investig. 2007;117:1926\u201332.","journal-title":"J Clin Investig"},{"key":"2263_CR30","doi-asserted-by":"publisher","first-page":"27436","DOI":"10.1074\/jbc.M704976200","volume":"282","author":"AD Nguyen","year":"2007","unstructured":"Nguyen AD, McDonald JG, Bruick RK, et al. Hypoxia stimulates degradation of 3-hydroxy-3-methylglutaryl-coenzyme a reductase through accumulation of lanosterol and hypoxia-inducible factor-mediated induction of insigs. J Biol Chem. 2007;282:27436\u201346.","journal-title":"J Biol Chem"},{"key":"2263_CR31","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1042\/BJ20111377","volume":"441","author":"GM Shen","year":"2012","unstructured":"Shen GM, Zhao YZ, Chen MT, et al. Hypoxia-inducible factor-1 (HIF-1) promotes LDL and VLDL uptake through inducing VLDLR under hypoxia. Biochem J. 2012;441:675\u201383.","journal-title":"Biochem J"},{"key":"2263_CR32","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1073\/pnas.1306942110","volume":"110","author":"AS Cowburn","year":"2013","unstructured":"Cowburn AS, Takeda N, Boutin AT. HIF isoforms in the skin differentially regulate systemic arterial pressure. Proc Natl Acad Sci USA. 2013;110:1770\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2263_CR33","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1172\/JCI36362","volume":"120","author":"MM Hickey","year":"2010","unstructured":"Hickey MM, Richardson T, Tao W, et al. The von hippel-lindau chuvash mutation promotes pulmonary hypertension and fibrosis in mice. J Clin Invest. 2010;120:827\u201339.","journal-title":"J Clin Invest"},{"key":"2263_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc3183","volume":"12","author":"B Keith","year":"2012","unstructured":"Keith B, Johnson RS, Simon MC. HIF1\u03b1 and HIF2\u03b1: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2012;12:9\u201322.","journal-title":"Nat Rev Cancer"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-022-02263-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-022-02263-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-022-02263-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T12:17:56Z","timestamp":1666009076000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-022-02263-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["2263"],"URL":"https:\/\/doi.org\/10.1007\/s10157-022-02263-4","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"type":"print","value":"1342-1751"},{"type":"electronic","value":"1437-7799"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"assertion":[{"value":"31 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}